Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources

Alliance Honors Survivors, Encourages Screening and Advocates for Research During National Cancer Survivors Month
In recognition of National Cancer Survivors Month this June, the Colorectal Cancer Alliance (Alliance) is shining a light on the more than 1.5 million colorectal cancer survivors in the United States, celebrating their strength while calling attention to increasing rates of colorectal cancer and the urgent need for more screening and research to end the disease.

Alliance Announces New Leadership Roles
The additions to the Colorectal Cancer Alliance's all bring deep expertise and a shared passion for the mission to end colorectal cancer in our lifetime.

Alliance Launches “Screen Smart” To Make Lifesaving Cancer Screenings Easier for Everyone
The Screen Smart initiative brings together insights from medical experts, researchers, and advocates to make colorectal cancer screening decisions easier for both patients and healthcare providers.